^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CCNE2 overexpression + PIK3CA mutation + ER positive

    i
    Other names: CCNE2, Cyclin E2, CYCE2, G1/S-Specific Cyclin-E2, PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, Phosphoinositide-3-kinase, catalytic, alpha polypeptide, Serine/threonine protein kinase PIK3CA, PtdIns-3-kinase subunit P110-alpha, PI3K-alpha, Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 KDa catalytic subunit alpha, Phosphatidylinositol 3-kinase, Catalytic, 110-KD, alpha, PI3-kinase P110 subunit alpha, PI3-kinase subunit alpha, PtdIns-3-kinase subunit alpha, PI3Kalpha, P110alpha, PI3K, ESR1, Era, ESR, NR3A1, ER, ER beta
    Entrez ID:
    2099; 5290; 9134
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    almost2years
    Exploratory analysis of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) PIK3CA mutated (mut) advanced breast cancer (aBC) treated with taselisib (TAS) and/or fulvestrant (FUL) reveals increased CCNE2 expression with poor outcome to placebo (PBO) + FUL but not TAS + FUL in SANDPIPER (AACR 2023)
    Elevated expression of CCNE2 has been associated with poor outcome in ER-positive breast cancer, and has been identified as part of gene signatures that predict disease progression in tamoxifen-resistant breast cancer or advanced breast cancer. Our analysis revealed an association between high CCNE2 expression and worse PFS in patients that received PBO + FUL. Further, this association was not observed in the patients that received the combination of TAS+FUL, which may inform future rational combination strategies for the clinical development of PI3K inhibitors in ER+/HER2- PIK3CAmut aBC.
    Clinical • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • CDK4 (Cyclin-dependent kinase 4) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • CCNE2 (Cyclin E2)
    |
    ER positive • EGFR mutation • HR positive • HER-2 negative • PIK3CA mutation • CCNE2 overexpression + PIK3CA mutation + ER positive
    |
    tamoxifen • fulvestrant • taselisib (GDC-0032)